Anna Panovska

6PUBLICATIONS
58CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classifiedHaematological tumoursCancer geneticsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 12, 2026
Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

|Dec 09, 2025
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Wojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz

|Dec 07, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Jennifer A Woyach, Lugui Qiu, Sebastian Grosicki

|Dec 08, 2023
Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naïve CLL patients.

Veronika Navrkalova, Karla Plevova, Lenka Radova

|Mar 25, 2022
Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene.

Lucie Poppova, Sarka Pavlova, Beatriz Gonzalez

|May 04, 2021
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.

Jitka Malcikova, Sarka Pavlova, Barbara Kunt Vonkova

Pageof 1

Frequent Collaborators

4 joint publications

Michael Doubek

3 joint publications

Sarka Pavlova

3 joint publications

Karla Plevova

3 joint publications

Jana Kotaskova